Drug Review Documents Hint At Impact Of Broad Changes At FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The last year has been a year of dramatic changes at FDA, as the agency implements the sweeping new authorities of the FDA Amendments Act. As industry tries to stay abreast of the new world of FDA, taking a closer look at how some of those changes played out in individual case studies – through the lens of Pharmaceutical Approvals Monthly’s drug review profiles – can yield some valuable lessons for companies preparing for the gauntlet of an FDA review.
You may also be interested in...
Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Every month, Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA’s own review documents, including the discipline reviews, decision memos, meeting minutes, emails, and other documents, we strive to illuminate the agency decision-making process.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.